HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
50 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC6A4
solute carrier family 6 member 4
Chromosome 17 · 17q11.2
NCBI Gene: 6532Ensembl: ENSG00000108576.11HGNC: HGNC:11050UniProt: B2R7Y7
2,401PubMed Papers
20Diseases
67Drugs
1Pathogenic Variants
FUNCTIONAL ROLE
Transporter
RESEARCH IMPACT
Highly Studied
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
monoamine transportintegrin bindingserotonin:sodium:chloride symporter activityprotein bindingobsessive-compulsive disordermajor depressive disorderdepressive disorderfibromyalgia
✩AI Summary

SLC6A4 encodes the serotonin transporter (SERT), which mediates serotonin reuptake from the synaptic cleft through cotransport with sodium and chloride ions in exchange for potassium 123456. This transporter is essential for serotonin homeostasis in the central nervous system and regulates serotonin levels across multiple physiological systems, including the gastrointestinal tract and blood platelets. In developing cortex, SERT controls serotonin uptake in glutamatergic neurons to organize sensory circuits, while in mature brain it primarily functions in raphe neurons to terminate synaptic serotonin signaling. The transport mechanism involves conformational cycling from outward-open to inward-open states, with Na+ and Cl- remaining bound throughout the cycle 123456. SLC6A4 gene variants significantly influence serotonin transport capacity, with combinations of polymorphisms capable of producing up to 40-fold differences in vitro 7. The 5-HTTLPR promoter polymorphism is extensively studied for associations with anxiety-related traits and psychiatric disorders. SLC6A4 short alleles moderate the effects of childhood adversity on adolescent mental health; notably, the short/short genotype amplified anxiety risk in children exposed to food insecurity 8. However, meta-analyses show no definitive associations between SLC6A4 variants and temporal lobe epilepsy susceptibility or pulmonary arterial hypertension 910, and associations with sensory processing sensitivity remain unconfirmed 11.

Sources cited
1
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 10407194
2
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 12869649
3
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 21730057
4
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 27049939
5
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 27756841
6
Serotonin transporter mechanism of Na+, Cl-, and K+ cotransport
PMID: 34851672
7
SLC6A4 variants can cause up to 40-fold differences in serotonin transport capacity
PMID: 21439906
8
SLC6A4 short/short allele moderates association between childhood food insecurity and adolescent anxiety
PMID: 38361316
9
No significant association between SLC6A4 variants and temporal lobe epilepsy susceptibility
PMID: 23065262
10
No significant association between SLC6A4 L/S polymorphism and pulmonary arterial hypertension
PMID: 32962488
11
SLC6A4 5-HTTLPR genotype not associated with sensory processing sensitivity
PMID: 32543106
Disease Associationsⓘ20
obsessive-compulsive disorderOpen Targets
0.69Moderate
major depressive disorderOpen Targets
0.64Moderate
depressive disorderOpen Targets
0.63Moderate
fibromyalgiaOpen Targets
0.61Moderate
panic disorderOpen Targets
0.60Moderate
attention deficit hyperactivity disorderOpen Targets
0.60Moderate
anxiety disorderOpen Targets
0.60Moderate
obesityOpen Targets
0.59Moderate
post-traumatic stress disorderOpen Targets
0.59Moderate
social anxiety disorderOpen Targets
0.59Moderate
diabetic neuropathyOpen Targets
0.58Moderate
bipolar disorderOpen Targets
0.58Moderate
generalized anxiety disorderOpen Targets
0.57Moderate
neuropathic painOpen Targets
0.56Moderate
muscular diseaseOpen Targets
0.54Moderate
bipolar I disorderOpen Targets
0.52Moderate
Stress urinary incontinenceOpen Targets
0.51Moderate
neuralgiaOpen Targets
0.50Moderate
PainOpen Targets
0.50Moderate
menopauseOpen Targets
0.48Moderate
Pathogenic Variants1
NM_001045.6(SLC6A4):c.1745dup (p.Thr583fs)Likely pathogenic
Obsessive-compulsive disorder
★☆☆☆2020→ Residue 583
View on ClinVar ↗
Drug Targets67
AMITIFADINEPhase III
Monoamine transporter inhibitor
obesity
AMITRIPTYLINEApproved
Norepinephrine transporter inhibitor
depressive disorder
AMITRIPTYLINE HYDROCHLORIDEApproved
Norepinephrine transporter inhibitor
major depressive disorder
AMOXAPINEApproved
Dopamine receptor antagonist
major depressive disorder
BICIFADINEPhase III
Monoamine transporter inhibitor
CENTANAFADINEPhase III
Monoamine transporter inhibitor
attention deficit hyperactivity disorder
CHLORPHENTERMINE HYDROCHLORIDEApproved
Serotonin transporter substrate
CITALOPRAMApproved
Serotonin transporter inhibitor
depressive disorder
CITALOPRAM HYDROBROMIDEApproved
Serotonin transporter inhibitor
major depressive disorder
CLOMIPRAMINEApproved
Serotonin transporter inhibitor
depressive disorder
CLOMIPRAMINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
DAPOXETINEPhase III
Serotonin transporter inhibitor
DASOTRALINEApproved
Monoamine transporter inhibitor
attention deficit hyperactivity disorder
DESVENLAFAXINEApproved
Norepinephrine transporter inhibitor
major depressive disorder
DESVENLAFAXINE FUMARATEApproved
Norepinephrine transporter inhibitor
major depressive disorder
DESVENLAFAXINE SUCCINATEApproved
Serotonin transporter inhibitor
DOTHIEPINApproved
Serotonin transporter inhibitor
major depressive disorder
DULOXETINEApproved
Norepinephrine transporter inhibitor
depressive disorder
DULOXETINE HYDROCHLORIDEApproved
Norepinephrine transporter inhibitor
fibromyalgia
ESCITALOPRAMApproved
Serotonin transporter inhibitor
major depressive disorder
ESCITALOPRAM OXALATEApproved
Serotonin transporter inhibitor
major depressive disorder
FAXELADOLPhase II
Mu opioid receptor agonist
fibromyalgia
FLUOXETINEApproved
Serotonin transporter inhibitor
depressive disorder
FLUOXETINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
major depressive disorder
FLUVOXAMINEApproved
Serotonin transporter inhibitor
depressive disorder
FLUVOXAMINE MALEATEApproved
Serotonin transporter inhibitor
GSK163090Phase II
Serotonin 1a (5-HT1a) receptor antagonist
anxiety disorder
IMIPRAMINEApproved
Norepinephrine transporter inhibitor
depressive disorder
IMIPRAMINE HYDROCHLORIDEApproved
Norepinephrine transporter inhibitor
enuresis
IMIPRAMINE PAMOATEApproved
Norepinephrine transporter inhibitor
INDALPINEUNKNOWN
Serotonin transporter inhibitor
LEVOMILNACIPRANApproved
Serotonin transporter inhibitor
fibromyalgia
LEVOMILNACIPRAN HYDROCHLORIDEApproved
Serotonin transporter inhibitor
LIAFENSINEPhase II
Monoamine transporter inhibitor
major depressive disorder
LUMATEPERONEApproved
Serotonin transporter inhibitor
MAZINDOLApproved
Monoamine transporter inhibitor
obesity
METHAMPHETAMINEApproved
Monoamine transporter inhibitor
attention deficit hyperactivity disorder
METHAMPHETAMINE HYDROCHLORIDEApproved
Monoamine transporter inhibitor
MIDOMAFETAMINEPhase III
Sodium-dependent dopamine transporter releasing agent
post-traumatic stress disorder
MILNACIPRANApproved
Norepinephrine transporter inhibitor
depressive disorder
MILNACIPRAN HYDROCHLORIDEApproved
Norepinephrine transporter inhibitor
fibromyalgia
NEFAZODONEApproved
Serotonin 2a (5-HT2a) receptor antagonist
major depressive disorder
NEFAZODONE HYDROCHLORIDEApproved
Serotonin 2a (5-HT2a) receptor antagonist
major depressive disorder
NOMIFENSINEApproved
Monoamine transporter inhibitor
major depressive disorder
NOMIFENSINE MALEATEUNKNOWN
Monoamine transporter inhibitor
NORTRIPTYLINEApproved
Serotonin transporter inhibitor
depressive disorder
NORTRIPTYLINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
NS-2359Phase II
Monoamine transporter inhibitor
attention deficit hyperactivity disorder
PAROXETINEApproved
Serotonin transporter inhibitor
depressive disorder
PAROXETINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
panic disorder
PAROXETINE MESYLATEApproved
Serotonin transporter inhibitor
PROTRIPTYLINEApproved
Serotonin transporter inhibitor
depressive disorder
PROTRIPTYLINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
SERTRALINEApproved
Serotonin transporter inhibitor
depressive disorder
SERTRALINE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
major depressive disorder
SIBUTRAMINEApproved
Monoamine transporter inhibitor
obesity
SIBUTRAMINE HYDROCHLORIDEPhase III
Monoamine transporter inhibitor
obesity
TEDATIOXETINEPhase II
Serotonin 2c (5-HT2c) receptor antagonist
major depressive disorder
TESOFENSINEPhase II
Monoamine transporter inhibitor
Pain
TRAZODONEApproved
Serotonin 2a (5-HT2a) receptor antagonist
depressive disorder
TRAZODONE HYDROCHLORIDEApproved
Serotonin 2a (5-HT2a) receptor antagonist
VENLAFAXINEApproved
Norepinephrine transporter inhibitor
VENLAFAXINE HYDROCHLORIDEApproved
Norepinephrine transporter inhibitor
major depressive disorder
VILAZODONEApproved
Serotonin transporter inhibitor
major depressive disorder
VILAZODONE HYDROCHLORIDEApproved
Serotonin transporter inhibitor
VORTIOXETINEApproved
Serotonin 1a (5-HT1a) receptor agonist
major depressive disorder
VORTIOXETINE HYDROBROMIDEApproved
Serotonin 1a (5-HT1a) receptor agonist
Related Genes
BDNFProtein interaction98%COMTProtein interaction98%DRD2Protein interaction98%DRD3Protein interaction98%DRD4Protein interaction98%MAOAProtein interaction98%
Tissue Expression6 tissues
Lung
100%
Heart
1%
Ovary
1%
Liver
1%
Bone Marrow
1%
Brain
1%
Gene Interaction Network
Click a node to explore
SLC6A4BDNFCOMTDRD2DRD3DRD4MAOA
PROTEIN STRUCTURE
Preparing viewer

PDB7TXT · 3.00 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.42Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.28 [0.20–0.42]
RankingsWhere SLC6A4 stands among ~20K protein-coding genes
  • #38of 20,598
    Most Researched2,401 · top 1%
  • #41of 1,025
    FDA-Approved Drug Targets53 · top 5%
  • #4,591of 5,498
    Most Pathogenic Variants1
  • #2,219of 17,882
    Most Constrained (LOEUF)0.42 · top quartile
Genes detectedSLC6A4
Sources retrieved50 papers
Response time—
📄 Sources
50▌
1
PMID: 32962488
J Int Med Res · 2020
1.00
2
New Biomarkers in Autoimmune Disease.
PMID: 28491876
J Immunol Res · 2017
1.00
3
SLC6A4 gene variants and temporal lobe epilepsy susceptibility: a meta-analysis.
PMID: 23065262
Mol Biol Rep · 2012
0.90
4
Association and gene-gene interaction of SLC6A4 and ITGB3 in autism.
PMID: 19588468
Am J Med Genet B Neuropsychiatr Genet · 2010
0.88
5
Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease.
PMID: 21439906
Curr Opin Pharmacol · 2011
0.80